- Oct 19, 2021 Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
- Sep 01, 2021 Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
- Aug 23, 2021 Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
- Aug 10, 2021 Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
- Aug 03, 2021 Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
- Jul 09, 2021 Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
- Jun 08, 2021 Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
- May 26, 2021 Foghorn Therapeutics to Present in Two Upcoming Investor Conferences
- May 17, 2021 Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
- May 11, 2021 Foghorn Therapeutics Provides Corporate Update
Displaying 71 - 80 of 92